๐ Financial Performance
- Revenue Growth: +8% YoY to โน20,689 million.
- Gross Margin: Improved to 52% from 47%.
- EBITDA: +24% YoY to โน5,853 million.
- Net Profit: +17% YoY to โน4,488 million.
- EBITDA Margin: Increased to 28% from 25%.
๐ Segmental Performance
- Agro Chemicals: Revenue grew by 14% YoY to โน20,439 million.
- Pharma: Revenue decreased to โน253 million from โน443 million.
๐ Regional Growth
- Domestic Market: Subdued due to delayed sowing and erratic monsoon.
- Exports: Sustained growth with new product launches.
๐ Profit Margin Comparison
- Gross Margin:
- Q1 FY25: 52%
- Q4 FY24: 47%
- Q1 FY24: 47%
- EBITDA Margin:
- Q1 FY25: 28%
- Q4 FY24: 25%
- Q1 FY24: 25%
- Net Profit Margin:
- Q1 FY25: 22%
- Q4 FY24: 21%
- Q1 FY24: 20%
๐ Financial Ratios
- ROCE: Improved to 37.1%.
- Net Sales to Trade Working Capital: Improved to 6.60.
- Debt/Equity Ratio: Stable at 0.01.
๐ Future Outlook
- Growth Drivers: New product launches, capacity expansion, and strategic acquisitions.
- Strategic Initiatives: Building Pharma CRDMO platform, expanding R&D capabilities, and strong cash flow management.
- Revenue Growth Target: Aiming for ~15% with sustained improvement in profits.
Disclosure: This document is not prepared for stock recommendation; it was created for educational purposes.
๐ www.profitfromit.in